In a recent study, a risk model based in inverse SOX2/SOX9 expression also identified EGFR signaling as a candidate for HNSCC patients with SOX2 low and SOX9 high expression pattern [41]. Here, EGFR is linked to head and neck squamous cell carcinoma.